Tolerance induction after organ transplantation, "delayed tolerance," via the mixed chimerism approach: Planting flowers in a battle field

Chimerism

Volumn 3, Issue 1, 2012, Pages 24-28

  Yamada, Yohei ^a   Benichou, Gilles ^a   Benedict Cosimi, A ^a   Kawai, Tatsuo ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Bone marrow transplantation; Chimerism; Kidney transplantation; Memory T cell; Tolerance

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2;

ALLOIMMUNITY; ALLOTRANSPLANTATION; ARTICLE; BONE MARROW TRANSPLANTATION; CD8+ T LYMPHOCYTE; CELL MATURATION; CELLULAR IMMUNITY; CHIMERA; HUMAN; IMMUNOMODULATION; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; KIDNEY TRANSPLANTATION; LYMPHOCYTE DEPLETION; MEMORY T LYMPHOCYTE; ORGAN DONOR; ORGAN TRANSPLANTATION; TRANSPLANTATION TOLERANCE;

EID: 84862680713     PISSN: 19381956     EISSN: 19381964     Source Type: Journal    
DOI: 10.4161/chim.20096     Document Type: Article

References (19)

1. Tomita Y, Khan A, Sykes M. Role of intrathymic clonal deletion and peripheral anergy in transplantation tolerance induced by bone marrow transplantation in mice conditioned with a nonmyeloablative regimen. J Immunol 1994; 153:1087-98;PMID:8027542.
2. Sharabi Y, Sachs DH. Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen. J Exp Med 1989; 169:493-502;PMID:2562984; http://dx.doi.org/10.1084/jem.169.2.493.
3. Kawai T, Cosimi AB, Colvin RB, Powelson J, Eason J, Kozlowski T, et al. Mixed allogeneic chimerism and renal allgraft tolerance in cynomolgus monkeys. Transplantation 1995; 59:256-62; PMID:7839449.
4. Kawai T, Poncelet A, Sachs DH, Mauiyyedi S, Boskovic S, Wee SL, et al. Long-term outcome and alloantibody production in a non-myeloablative regimen for induction of renal allograft tolerance. Transplantation 1999; 68: 1767-75; PMID:10609955; http://dx.doi.org/10.1097/ 00007890-199912150-00022.
5. Kawai T, Sogawa H, Boskovic S, Abrahamian G, Smith RN, Wee SL, et al. CD154 blockade for induction of mixed chimerism and prolonged renal allograft survival in nonhuman primates. Am J Transplant 2004; 4:1391-8;PMID:15307826; http://dx.doi.org/10.1111/j.1600- 6143.2004.00523.x
6. Spitzer TR, Delmonico F, Tolkoff-Rubin N, McAfee S, Sackstein R, Saidman S, et al. Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: the induction of allograft tolerance through mixed lymphohematopoietic chimerism. Transplantation 1999; 68:480-4; PMID:10480403; http://dx.doi.org/10.1097/00007890-199908270-00006.
7. Kawai T, Cosimi AB, Spitzer TR, Tolkoff-Rubin N, Suthanthiran M, Saidman SL, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008; 358:353-61; PMID: 18216355; http://dx.doi.org/10.1056/NEJMoa071074.
8. Khan A, Tomita Y, Sykes M. Thymic dependence of loss of tolerance in mixed allogeneic bone marrow chimeras after depletion of donor antigen. Peripheral mechanisms do not contribute to maintenance of tolerance. Transplantation 1996; 62:380-7; PMID: 8779687; http://dx.doi.org/10.1097/00007890-199608150-00014.
9. Nadazdin O, Boskovic S, Murakami T, O'Connor DH, Wiseman RW, Karl JA, et al. Phenotype, distribution and alloreactive properties of memory T cells from cynomolgus monkeys. Am J Transplant 2010; 10:1375-84; PMID:20486921; http://dx.doi.org/10.1111/j.1600-6143.2010.03119.x
10. Baker RJ, Hernandez-Fuentes MP, Brookes PA, Chaudhry AN, Lechler RI. The role of the allograft in the induction of donor-specific T cell hyporesponsiveness. Transplantation 2001; 72:480-5; PMID: 11502979; http://dx.doi.org/10.1097/00007890-200108150-00020.
11. Gebauer BS, Hricik DE, Atallah A, Bryan K, Riley J, Tary-Lehmann M, et al. Evolution of the enzymelinked immunosorbent spot assay for post-transplant alloreactivity as a potentially useful immune monitoring tool. Am J Transplant 2002; 2:857-66; PMID: 12392292; http://dx.doi.org/10.1034/j.1600-6143.2002.20908.x
12. Marelli-Berg FM, Lechler RI. Antigen presentation by parenchymal cells: a route to peripheral tolerance? Immunol Rev 1999; 172:297-314; PMID:10631955; http://dx.doi.org/10.1111/j.1600-065X.1999.tb01374.x
13. Han S, Asoyan A, Rabenstein H, Nakano N, Obst R. Role of antigen persistence and dose for CD4+ T-cell exhaustion and recovery. Proc Natl Acad Sci U S A 2010; 107:20453-8; PMID:21059929; http://dx.doi.org/10.1073/pnas.1008437107.
14. Cooper JC, Morgan G, Harding S, Subramanyam M, Majeau GR, Moulder K, et al. Alefacept selectively promotesNK cell-mediated deletion of CD45R0+ human T cells. Eur J Immunol 2003; 33:666-75; PMID: 12616487; http://dx.doi.org/10.1002/eji.200323586.
15. da Silva AJ, Brickelmaier M, Majeau GR, Li Z, Su L, Hsu YM, et al. Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells. J Immunol 2002; 168:4462-71; PMID:11970990.
16. Gordon KB, Vaishnaw AK, O'Gorman J, Haney J, Menter A & Alefacept Clinical Study Group. Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts. Arch Dermatol 2003; 139:1563-70; PMID: 14676071; http://dx.doi.org/10.1001/archderm.139.12.1563.
17. Krueger GG. Selective targeting of T cell subsets: focus on alefacept-a remittive therapy for psoriasis. Expert Opin Biol Ther 2002; 2:431-41; PMID:11955280; http://dx.doi.org/10.1517/14712598.2.4.431.
18. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441:235-8; PMID: 16648838; http://dx.doi.org/10.1038/nature04753.
19. Korn T, Bettelli E, Gao W, Awasthi A, Jäger A, Strom TB, et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007; 448:484-7; PMID:17581588; http://dx.doi.org/10.1038/nature05970